Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06547099 · ClinicalTrials.gov registry record
Study to Understand Novel Biomarkers in Researching Dementia
A clinical trial of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- 1,800
- Enrollment target
- 1
- Study location
NCT06547099: Recruiting study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Washington University School of Medicine.
NCT06547099 is a study of Alzheimer Disease and Mild Cognitive Impairment that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 1,800 participants, below the 2,745-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06547099, a study of Alzheimer Disease and Mild Cognitive Impairment, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- 1,800 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Clinical tau PET
- DIAGNOSTIC_TEST Clinical amyloid test
- OTHER Research blood collection
- OTHER Cognitive assessments
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2024-08-14 |
| Est. Completion | 2028-12 |
What NCT06547099 shows while recruiting
NCT06547099 is an observational study that tracks outcomes without assigning an intervention. Its 1,800 participants enrollment target places it among the larger protocols in the corpus, below the 2,745-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (34% lower).
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 4 interventions - of which Clinical tau PET is the first listed.
NCT06547099 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06547099 about?
NCT06547099 is a clinical study titled "Study to Understand Novel Biomarkers in Researching Dementia". The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and pre...
What is the current status of trial NCT06547099?
This trial is currently recruiting. The enrollment target is 1,800 participants. The study started on 2024-08-14. Estimated completion is 2028-12.
What conditions does trial NCT06547099 study?
This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia.
What interventions are being tested in trial NCT06547099?
The interventions under investigation include: Clinical tau PET (DIAGNOSTIC_TEST), Clinical amyloid test (DIAGNOSTIC_TEST), Research blood collection (OTHER), Cognitive assessments (OTHER).
Who is sponsoring clinical trial NCT06547099?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06547099 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06547099's enrollment target sits among peer trials
1,800 22nd of 306 higher than 284 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI